NICE rejects MS symptom-relieving treatments

NICE has rejected the NHS use of two treatments indicated to relieve certain symptoms of multiple sclerosis (MS).

People who are already receiving Sativex or Fampyra on the NHS should be able to continue treatment until they and their NHS clinician decide it is appropriate to stop.
People who are already receiving Sativex or Fampyra on the NHS should be able to continue treatment until they and their NHS clinician decide it is appropriate to stop.

In its updated clinical guideline on the management of MS in primary and secondary care, NICE advised that patients should not be offered the cannabis-derived oromucosal spray Sativex to treat spasticity or the oral treatment fampridine (Fampyra) to improve walking disability. NICE judged that neither option was cost-effective.

NICE has issued positive opinions on the oral MS treatments dimethyl fumarate (Tecfidera), teriflunomide (Aubagio), and fingolimod (Gilenya) and parenteral alemtuzumab (Lemtrada).

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Further monthly injectable migraine prophylactic launched

Further monthly injectable migraine prophylactic launched

With the launch of Emgality (galcanezumab), prescribers...

Vitamin D3 Supplements

Formulations and indications of colecalciferol preparations.

Avoid gout drug in patients with major cardiovascular conditions, says MHRA

Avoid gout drug in patients with major cardiovascular conditions, says MHRA

Treatment with febuxostat (Adenuric) should be avoided...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Colestid Orange. Use our constantly updated...